Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
BDC-4182 · 1 trial · 2 indications
Escalation period
Escalation period
| Arm | Type | Description |
|---|---|---|
| Dose Escalation | EXPERIMENTAL | Escalating doses followed by backfill of selected doses |
| Dose Expansion | EXPERIMENTAL | Expansion at determined RP2D |
| Name | Type | Description |
|---|---|---|
| BDC-4182 | DRUG | Immune stimulating antibody conjugate (ISAC), consisting of an anti-claudin 18.2 monoclonal antibody conjugated to a TLR 7/8 dual agonist |
Key Inclusion Criteria: * Has disease that is measurable by Response Evaluation Criteria in Solid Tumors (RECIST) v.1.1. * Subjects must have histologically/cytologically confirmed gastric or gastroesophageal cancer that is metastatic (Stage 4) or unresectable (Stage 3). * Subjects must have receiv...
BDC-4182 is an investigational small molecule being studied for the treatment of metastatic gastric cancer adenocarcinoma and gastroesophageal adenocarcinoma. It is currently in Phase 1 clinical development as a single agent for advanced gastric and gastroesophageal cancer.
BDC-4182 is being developed by Bolt Biotherapeutics, Inc., a biopharmaceutical company. The company is listed on the stock exchange under the ticker symbol BOLT.
BDC-4182 is in Phase 1 clinical development. It is an investigational drug and has not been approved by regulatory authorities. A first-in-human study is currently recruiting participants to evaluate its safety and efficacy.
BDC-4182 is being studied in a Phase 1 clinical trial with the identifier NCT06921837. This first-in-human study is evaluating BDC-4182 as a single agent in advanced gastric and gastroesophageal cancer, with an enrollment target of 122 participants.
No alternative names for BDC-4182 have been disclosed. It is identified solely by its code name BDC-4182 in clinical trial registrations and by the developer, Bolt Biotherapeutics.